SILVER SPRING
Tzield indication expanded to pediatric type 1 diabetes
- Sponsor
- Sanofi $SNY
- Drug
- Tzield · teplizumab-mzwv
- Indication
- stage 3 type 1 diabetes
FDA approved Tzield (teplizumab-mzwv) for delaying stage 3 type 1 diabetes onset in children as young as one year old.
What this means
Tzield is an antibody drug that targets immune cells to delay the progression of type 1 diabetes in children. Today FDA expanded its approval to include kids as young as one year old who are at risk of developing full-blown diabetes. This decision could help protect more young children from needing insulin injections by slowing the disease's advance during its earliest stages.
Drug Watch — recent news on Tzield
- First disease-modifying therapy to delay Type 1 diabetes recommended in NHS - Healthcare Today
- FDA Approves Tzield for Children With New Stage 3 Type 1 Diabetes - Ophthalmology Advisor
- A diabetes drug now on the NHS can buy your child three more years before insulin, and here's how it works - OkDiario
- FDA Approves Tzield for Children With New Stage 3 Type 1 Diabetes - Gastroenterology Advisor
- UC Davis Unveils Therapy to Delay Type 1 Diabetes - Mirage News